Stockscreener 앱 받기
18.50
12.05%
1.99
전일 마감가:
$16.51
열려 있는:
$16.75
하루 거래량:
126.81K
Relative Volume:
1.38
시가총액:
$618.22M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.05%
1개월 성능:
-22.82%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.75
$19.00
1주일 범위
$15.31
$19.16
52주 변동 폭
$15.31
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
명칭
Mbx Biosciences Inc
전화
(317) 989-3100
주소
12406 HORESHAM STREET, CARMEL
MBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MBX | 18.50 | 618.22M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
MBX Biosciences (NYSE:MBX) Shares Up 6.5%Here's Why - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap DownHere's What Happened - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
MBX Biosciences Announces Last Subject Last Visit in Phase - GlobeNewswire
Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia - Marketscreener.com
MBX Biosciences (NYSE:MBX) Reaches New 12-Month Low – Here’s Why - Defense World
MBX Biosciences (NYSE:MBX) Sets New 1-Year LowTime to Sell? - MarketBeat
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data (NASDAQ:MBX) - Seeking Alpha
Behind the Bell: MBX Biosciences - Nasdaq
MBX Biosciences Reports Q3 2024 Financial Progress - MSN
Wellington Management Group LLP Acquires New Stake in MBX Biosci - GuruFocus.com
MBX Biosciences Inc. (MBX) Quarterly 10-Q Report - Quartzy
MBX Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
MBX Biosciences Secures $251M in IPO, Advances Clinical Pipeline with Strong Cash Position | MBX Stock News - StockTitan
MBX Biosciences (NYSE:MBX) Shares Up 8.2%Time to Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Up 6.8%Should You Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Sets New 52-Week LowTime to Sell? - MarketBeat
MBX Biosciences to Participate in Upcoming November Investor Conferences - The Manila Times
MBX Biosciences (NYSE:MBX) Shares Down 4.5%Here's What Happened - MarketBeat
MBX Biosciences sets IPO terms with plans to raise up to $136 million - MSN
MBX Biosciences, Inc.'s (NYSE:MBX) Quiet Period To End on October 23rd - MarketBeat
MBX Biosciences, Inc.’s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Stock Price Down 4%Here's Why - MarketBeat
MBX Bio drops despite bullish views on Street - MSN
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - BNN Bloomberg
MBX Biosciences (NYSE:MBX) Shares Up 4.6%Here's What Happened - MarketBeat
MBX Biosciences earns Buy rating at three investment firms - MSN
MBX Bio stock drops despite bullish initiations (NASDAQ:MBX) - Seeking Alpha
Guggenheim bullish on MBX Biosciences stock, driven by MBX 2109 potential - Investing.com Canada
MBX Biosciences outlook solid with JPMorgan's overweight rating, eyes key catalysts in next 12 months - Investing.com India
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements - Investing.com India
MBX Biosciences earns Buy rating at three investment firms By Investing.com - Investing.com Canada
Guggenheim Begins Coverage on MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Now Covered by JPMorgan Chase & Co. - MarketBeat
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements By Investing.com - Investing.com South Africa
MBX Biosciences (NYSE:MBX) Stock Price Down 3.5%Should You Sell? - MarketBeat
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ - GlobeNewswire
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - Yahoo Finance
Mbx Biosciences Inc (MBX) 재무 분석
Mbx Biosciences Inc (MBX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):